Values as of: 2024-11-03
COMMON STOCK | Medical Devices |
Last Closing
USD 225.18Change
0.00 (0.00)%Market Cap
USD 21.88BVolume
0.49MAnalyst Target
USD 175.00Verdict
Verdict
STERIS plc provides infection prevention products and services worldwide. It operates through three segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument, devices, and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The AST segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of contract sterilization and laboratory facilities, as well as integrated sterilization equipment and control systems to medical device manufacturers and research institutions. The Life Sciences segment designs, manufactures, and sells consumable products, such as pharmaceutical detergents, cleanroom disinfectants and sterilants, pharmaceutical grade and research sterilizers and washers, sterility assurance and maintenance products, vaporized hydrogen peroxide room decontamination systems and sterilizers, and high purity water and pure steam generators. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. It serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is headquartered in Mentor, Ohio.
Company Website : https://www.steris.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| ABT | Abbott Laboratories |
N/A |
USD 205.71B |
| MDT | Medtronic PLC |
N/A |
USD 118.35B |
| ZBH | Zimmer Biomet Holdings Inc |
N/A |
USD 21.28B |
| SNN | Smith & Nephew SNATS Inc |
N/A |
USD 12.71B |
| BIO | Bio-Rad Laboratories Inc |
N/A |
USD 10.14B |
| GMED | Globus Medical |
N/A |
USD 10.01B |
| PEN | Penumbra Inc |
N/A |
USD 7.95B |
| GKOS | Glaukos Corp |
N/A |
USD 7.18B |
| INSP | Inspire Medical Systems Inc |
N/A |
USD 5.82B |
| ITGR | Integer Holdings Corp |
N/A |
USD 4.24B |
| Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|---|
| UTRN | Vesper U.S. Large Cap Sho.. | 4.11 % | 0.00 % |
N/A |
USD 0.02B |
| EVX | VanEck Environmental Serv.. | 0.00 % | 0.56 % |
N/A |
N/A |
| HIG:CA | Global Healthcare Income .. | 0.00 % | 1.02 % |
N/A |
CAD 0.05B |
| HIG-U:CA | 0.00 % | 0.00 % |
N/A |
N/A |
| Market Performance vs. Industry/Classification (Medical Devices) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | 2.42% | 67% | D+ | 42% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 2.42% | 67% | D+ | 43% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | 3.66% | 57% | F | 33% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 3.66% | 57% | F | 35% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | 54.78% | 78% | C+ | 75% | C | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 54.78% | 78% | C+ | 75% | C | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 10.98% | 61% | D- | 69% | C- | ||
| Dividend Return | 11.88% | 61% | D- | 66% | D+ | ||
| Total Return | 0.90% | 38% | F | 21% | F | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 18.71% | 97% | N/A | 57% | F | ||
| Risk Adjusted Return | 63.50% | 97% | N/A | 79% | B- | ||
| Market Capitalization | 21.88B | 92% | A | 92% | A | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers median on a price to book value basis.
The company has under performed its peers on annual average total returns in the past 5 years.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
This stock has shown below median dividend growth in the previous 5 years compared to its sector.
